Myomo Announces Free Screening Days in Over 20 Cities Nationwide

Screenings Offer Free, Convenient Hands-on Evaluations of MyoPro® Powered Brace
 

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, announces a nationwide program of free screening days to be held in collaboration with its Centers of Excellence, other orthotics and prosthetics practices and its rehabilitation therapy partners.

Myomo and its partners will offer potential users a convenient chance to be evaluated by clinical specialists and to examine a MyoPro powered brace for themselves to determine if MyoPro might help them overcome upper-limb paralysis caused by stroke, brachial plexus injury or other neuromuscular disease or injury.

During May, free open screening clinics are planned for Boston; Hartford, Conn.; New York City; Livonia, Madison Heights, Ann Arbor, Grand Rapids, Grand Blanc and Detroit, Mich.; Chicago; Milwaukee; Cincinnati, Cleveland and Columbus, Ohio; Salt Lake City; and San Francisco. Screenings at additional locations are planned for June.

Exact dates and locations, more information and no-cost, no obligation registration may be found at www.myomo.com/screening.

This nationwide rollout of the screening program follows a successful pilot screening program at Geauga Rehabilitation Engineering (GRE), a Myomo Center of Excellence partner, during the first quarter of 2018 in Cleveland, Columbus, Cincinnati and Detroit.

“Many individuals with a paralyzed arm and hand after a stroke or injury are told they’ll never use that limb again for the rest of their lives,” said Cliff Conneighton, Myomo’s Chief Marketing Officer. “With our MyoPro powered arm brace, many are able to regain movement and restore functional ability so they can return to work, feed themselves, and perform daily living tasks. We are launching this screening campaign to educate and assist more individuals, families, physicians and therapists about the benefit of the MyoPro myoelectric orthosis.”

Most commercial healthcare plans, multiple Medicaid plans, workers’ compensation and Medicare Advantage plans have covered the device based on medical necessity and the potential to reduce healthcare costs. Eligible veterans may receive a MyoPro through their local VA Medical Center.

About Myomo
Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

Forward Looking Statements
This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

Contacts

For Myomo:
ir@myomo.com
or
Investor Relations:
PCG Advisory
Vivian Cervantes, 646-863-6274
vivian@pcgadvisory.com
or
Public Relations:
Greenough
Rachel Robbins, 617-275-6521
rrobbins@greenough.biz

 

 
 

Source: Myomo, Inc.

Back to news